Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Few Clouds On High-Priced, Ultra-Orphan Drug Horizon

29 Apr 2017

• By Mary Jo Laffler and Emily Hayes

Money Wave

Related Content

Biogen Forecasts Gradual Launch For Life-Transforming Drug Spinraza

26 Jan 2017

Trump Throws Pharma A Curve Ball On The Third Day Of J.P. Morgan

12 Jan 2017

Biogen Staying "Laser-Focused" On Neuroscience

25 Apr 2017

Biogen’s Spinraza Needs Long-Term Confirmatory Data, Says EMA

25 Apr 2017

PTC Gambles On Success With <em>Emflaza</em>; Says Price Revision Is Needed

16 Mar 2017

Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage

02 Mar 2017

Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016

28 Dec 2016

Who Speaks For The White House On Drug Prices? Industry Better Hope It Is Not Donald Trump

14 Mar 2017

Will Physician Demand For Repatha Put Pressure On Payer Restrictions?

20 Mar 2017

Orphan Drug Economics: What’s The Right Price For Rare Disease Drugs?

15 Nov 2013

Related Companies

BioMarin Pharmaceutical Inc.

Biogen, Inc.

Ionis Pharmaceuticals, Inc.

Sarepta Therapeutics, Inc.

Marathon Pharmaceuticals LLC

PTC Therapeutics, Inc.

Additional Topics

Launches Pricing Debate Market Access Pricing Strategies Commercial Government Payers BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.